Navigation Links
Mount Sinai researchers to test first gene therapy For Alzheimer's patients
Date:11/17/2009

Mount Sinai School of Medicine is one of 12 sites nationwide participating in the first Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease. The study is the first multicenter neurosurgical intervention in Alzheimer's research in the U.S.

The experimental treatment utilizes a viral-based gene transfer system, CERE-110, that makes Nerve Growth Factor (NGF), a naturally occurring protein that helps maintain nerve cell survival in the brain. CERE-110 has been previously studied in animals, where it reversed brain degeneration in aged monkeys and rats. For this study, CERE-110, will be injected by a neurosurgeon directly into the nucleus basalis of Meynert (NBM) of the brain, an area where neuronal death occurs in Alzheimer's patients.

In animal studies, NGF has been shown to support the survival and function of the neurons that deteriorate in Alzheimer's patients. These neurons produce the chemical acetylcholine, which is important in memory and cognitive function. The hope is that improvement of this system's function may lead to better memory performance in Alzheimer's patients.

A Phase 1 study in Alzheimer's patients has been conducted at Rush University in Chicago and the University of California San Diego, where researchers observed increases in brain metabolism in several cortical regions of the brain at 6- and 12-month follow-up in some of the participants. With follow-up ranging from six months to more than four years post-treatment, there have been no side effects thought to be caused by CERE-110.

Participants in the Phase 2 study will be randomly placed into one of two treatment groups, with half receiving CERE-110 via neurosurgery and half receiving placebo surgery without any cranial injections. Once the study is completed, and if the results are promising, participants in the placebo group will be eligible to be treated with CERE-110. All participants will receive a thorough medical examination and cognitive testing. In addition, participants will be closely monitored by a team of physicians for the duration of the two-year study. Participants will also be encouraged to participate in long-term follow-up.


'/>"/>

Contact: Mount Sinai Press Office
newsnow@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Paramount Acquisition Corp. Announces Chem Rx Expansion into Albany, New York Market
2. Mount Sinai & ENT and Allergy Associates, LLP affiliate to fight cancer
3. Paramount Acquisition Corp. Announces Record Date of October 1, 2007 for Proposed Acquisition of Chem Rx
4. Kaiser Permanente study: Alcohol amount, not type -- wine, beer, liquor -- triggers breast cancer
5. Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx
6. Fred Hutchinson Cancer Research Center Announces the First-Ever Expedition to an Unclimbed Mountain in the Name of Cancer Research
7. Iron Mountain Acquires RMS Services - USA, Inc.
8. Surge in U.S. Cases of Rocky Mountain Spotted Fever
9. Oregon Scientific to Sponsor First-Ever Rock Concert on Mount Everest
10. Mount Sinai recognized as Center of Excellence for Research in Alzheimers disease
11. Paramount Completes Acquisition of Chem Rx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , ... March 23, 2017 , ... ... families and businesses of the greater Fort Collins area, has unveiled a collaboration ... ongoing community involvement program. Donations to this worthy cause may now be made ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital ... President and Director, AMN Healthcare: Susan Salka , 43rd President of the United ... The Big Fight My Life In and Out of the Ring: Sugar Ray Leonard , ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... that help improve all aspects of people’s health and nutrition, announced its product ... products. , Natural Subsistence develops nutritional supplements that help people improve all ...
(Date:3/23/2017)... New Port Richey, FL (PRWEB) , ... March 23, 2017 , ... ... delighted to announce that 2017 marks the 40th Anniversary of ABQAURP’s dedication to Health ... that ABQAURP honors those who have contributed not only to the association, but also ...
(Date:3/23/2017)... (PRWEB) , ... March 23, ... ... Reports: Complying with European Guidelines and the New MEDDEV 2.7/1 Rev. 4 ... p.m. ET, http://www.fdanews.com/mdclineval                  , How will the new EU MDR ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 2017  Drug diversion is a significant contributing ... overdoses. A new oral fluid monitoring test, announced ... reports more detailed and actionable information to clinicians ... therapy adherence, patient safety, and help to identify ... fluid Rx Evaluation (CORE) system is the first ...
(Date:3/23/2017)... - INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") ... that AB Laboratories Inc. ("AB Labs") has successfully completed ... the Access to Cannabis for Medical Purposes Regulations ("ACMPR") ... The facility, which was licensed for Cultivation ... at half capacity, with full production capacity scheduled by ...
(Date:3/23/2017)... -- Piramal Pharma Solutions (PPS), una ... de Stuart E. Needleman como director ... completa para su base de clientes farmacéuticos global ... crecimiento y ejecución de las ofertas PPS. Como ... las actividades de desarrollo empresarial global para el ...
Breaking Medicine Technology: